市場調査レポート

商品コード

1438063

エリスロポエチン製剤市場の2030年までの予測：タイプ別、製品別、流通チャネル別、用途別、エンドユーザー別、地域別の世界分析

Erythropoietin Drugs Market Forecasts to 2030 - Global Analysis By Type (Biosimilars and Biologics), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Products), Distribution Channel, Application, End User and By Geography

出版日: 2024年02月02日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 652,131円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 824,985円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 997,839円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,178,550円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のエリスロポエチン製剤市場は2023年に107億米ドルを占め、予測期間中のCAGRは13.2％で成長し、2030年には256億米ドルに達すると予測されています。

エリスロポエチン製剤は、腎臓で自然に産生されるホルモンであるエリスロポエチンの遺伝子組換え型製剤を含む薬剤クラス別です。これらの薬剤は、赤血球の合成を刺激して増加させるように設計されており、貧血に関連する症状の管理に効果的です。エリスロポエチン製剤は、赤血球数を増加させることにより、脱力感、呼吸困難、めまいなどの貧血症状を治療し、患者の日常機能の改善につながります。

世界保健機関（WHO）によると、世界では5歳未満の子どもの42％、妊婦の40％が貧血です。

貧血の増加

貧血は、赤血球数の減少またはヘモグロビン量の減少を特徴とする病態であり、血液中の酸素運搬能力の低下につながります。EPO製剤は、赤血球の産生を促進することで、貧血の管理に重要な役割を果たします。さらに、EPO製剤は、化学療法による貧血を管理し、生活の質を改善するために、がん患者に処方されることが多いです。これらの疾患の有病率の増加は、貧血の全体的な負担を増加させる一因となっており、EPO製剤の需要を牽引しています。

副作用の可能性

エリスロポエチン製剤市場は、製剤の使用に伴う副作用の発生という潜在的な市場抑制要因に直面しています。重大な懸念事項の一つは、エリスロポエチン製剤の投与に伴う血栓症や高血圧などの心血管イベントのリスクです。さらに、もう一つの潜在的な副作用として、純赤血球無形成症（PRCA）の発症があり、これは稀ではあるが、赤血球の産生が突然停止することを特徴とする重篤な状態です。

ヘルスケア意識の向上

ヘルスケアに対する意識の高まりは、エリスロポエチン製剤市場の極めて重要な促進要因となっています。貧血を含む健康状態に対する意識が患者や医療従事者の間で高まり続ける中、貧血に関連する合併症の管理におけるエリスロポエチン製剤の重要性に対する認識が高まっています。さらに、慢性腎臓病などエリスロポエチン製剤が重要な役割を果たす疾患に対して、タイムリーで効果的な治療を求める患者が増えています。これらの要因が市場の需要を後押ししています。

新たな代替薬

科学的・医学的研究の進展に伴い、非薬理学的介入や代替薬物療法を含む新たな治療選択肢が注目されるようになり、エリスロポエチン製剤の優位性に対する課題となっています。さらに、市場におけるバイオシミラーの利用可能性と採用の増加は、価格圧力と市場シェア競争につながり、ブランド化されたエリスロポエチン製剤の収益に影響を与える可能性があります。

COVID-19の影響

エリスロポエチン製剤市場は、COVID-19パンデミックによる顕著な影響を経験しました。貧血用エリスロポエチン製剤を含む緊急性のない医療処置や治療が延期または遅延され、市場全体の需要に影響を与えました。さらに、医薬品サプライチェーンの混乱、移動制限、労働力不足が、エリスロポエチン製剤の生産と流通の障害となった。

予測期間中、がん分野が最大となる見込み

がん分野が最大のシェアを占めると推定されます。がん患者は、病気自体の影響や化学療法の副作用として貧血を頻繁に経験します。エポエチン・アルファなどのエリスロポエチン製剤は、赤血球の産生を刺激することでがん患者の貧血に対処するために使用されます。さらに、エリスロポエチン療法は患者の健康状態を改善し、酸素を運搬する赤血球の十分なレベルを維持することで、より効果的ながん治療を可能にする可能性があります。

予測期間中、生物学的製剤分野のCAGRが最も高くなると予想されています。

生物製剤セグメントは、予測期間中に有利な成長を遂げると予測されています。生物製剤は、骨髄での赤血球産生を刺激するエリスロポエチンの自然な機能を模倣するように設計されています。エリスロポエチン生物学的製剤は、慢性腎臓病、がん化学療法、その他の特定の病状に伴う貧血に対処するために一般的に使用されています。さらに、エリスロポエチンベースの薬剤を含む生物学的製剤は、貧血に的を絞った効果的な治療を提供することで、患者の治療に大きく貢献しています。

最大のシェアを占める地域

北米は、強固なヘルスケア・インフラ、技術革新、有病率の高さにより、推定期間中最大の市場シェアを占めました。特に透析を受けているCKD患者やがん治療を受けている患者における貧血の蔓延が、北米におけるエリスロポエチン製剤の需要を押し上げています。さらに、この地域はバイオテクノロジーと製薬研究の最前線でもあり、エリスロポエチン製剤の開発における継続的な技術革新を後押ししています。

CAGRが最も高い地域：

アジア太平洋地域は、世界の製薬産業に大きく貢献していることから、予測期間中に有益な成長を遂げることが期待されます。中国やインドのような国々が、エリスロポエチン製剤の生産と消費の主要プレーヤーとして台頭してきました。同地域の医薬品セクターは、研究開発活動が活発であることから、イノベーションが促進され、新たなEPO製剤が導入されています。さらに、アジア太平洋地域の進化するヘルスケア・インフラと医療費の増加は、エリスロポエチン製剤市場の成長に寄与しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第11章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

Johnson & Johnson Services, Inc.
AstraZeneca
Amgen, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Pfizer Inc
LG Chem
F. Hoffmann-La Roche Ltd.
Sun Pharmaceutical Industries Ltd.
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd
Ranbaxy Laboratories
Roche Diagnostics

図表

List of Tables

Table 1 Global Erythropoietin Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 4 Global Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 5 Global Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 6 Global Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 7 Global Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 8 Global Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 9 Global Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 10 Global Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 11 Global Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 12 Global Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 13 Global Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 14 Global Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 15 Global Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 16 Global Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 17 Global Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 18 Global Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 19 Global Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 20 Global Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 21 Global Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 22 Global Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 Global Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 24 North America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 25 North America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 26 North America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 27 North America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 28 North America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 29 North America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 30 North America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 31 North America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 32 North America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 33 North America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 34 North America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 35 North America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 36 North America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 37 North America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 38 North America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 39 North America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 40 North America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 41 North America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 42 North America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 43 North America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 44 North America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 45 North America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 46 North America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 47 Europe Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 48 Europe Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 49 Europe Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 50 Europe Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 51 Europe Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 52 Europe Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 53 Europe Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 54 Europe Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 55 Europe Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 56 Europe Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 57 Europe Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 58 Europe Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 59 Europe Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 60 Europe Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 61 Europe Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 62 Europe Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 63 Europe Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 64 Europe Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 65 Europe Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 66 Europe Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 67 Europe Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 68 Europe Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 69 Europe Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 70 Asia Pacific Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 71 Asia Pacific Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 72 Asia Pacific Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 73 Asia Pacific Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 74 Asia Pacific Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 75 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 76 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 77 Asia Pacific Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 78 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 79 Asia Pacific Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 80 Asia Pacific Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 81 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 82 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 83 Asia Pacific Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 84 Asia Pacific Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 85 Asia Pacific Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 86 Asia Pacific Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 87 Asia Pacific Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 88 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 89 Asia Pacific Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 90 Asia Pacific Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 91 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 92 Asia Pacific Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 93 South America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 94 South America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 95 South America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 96 South America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 97 South America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 98 South America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 99 South America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 100 South America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 101 South America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 102 South America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 103 South America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 104 South America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 105 South America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 106 South America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 107 South America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 108 South America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 109 South America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 110 South America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 111 South America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 112 South America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 113 South America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 114 South America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 115 South America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 116 Middle East & Africa Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 117 Middle East & Africa Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
Table 118 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
Table 119 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
Table 120 Middle East & Africa Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
Table 121 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
Table 122 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
Table 123 Middle East & Africa Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
Table 124 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
Table 125 Middle East & Africa Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 126 Middle East & Africa Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 127 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 128 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 129 Middle East & Africa Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 130 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
Table 131 Middle East & Africa Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
Table 132 Middle East & Africa Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
Table 133 Middle East & Africa Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
Table 134 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 135 Middle East & Africa Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 136 Middle East & Africa Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
Table 137 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 138 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC25051

According to Stratistics MRC, the Global Erythropoietin Drugs Market is accounted for $10.7 billion in 2023 and is expected to reach $25.6 billion by 2030 growing at a CAGR of 13.2% during the forecast period. Erythropoietin drugs are a class of medications that include recombinant forms of erythropoietin, a hormone produced naturally in the kidneys. These drugs are designed to stimulate and increase the synthesis of red blood cells, making them effective in managing conditions associated with anaemia. Erythropoietin medications treat anaemia symptoms such as weakness, dyspnea, and vertigo by raising red blood cell counts, leading to improved daily functioning for patients.

According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic.

Market Dynamics:

Driver:

Rising prevalence of anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin, leading to reduced oxygen-carrying capacity in the blood. EPO drugs play a crucial role in managing anaemia by stimulating the production of red blood cells. Moreover, EPO drugs are often prescribed to cancer patients to manage chemotherapy-induced anaemia and improve their quality of life. The increasing prevalence of these conditions contributes to the overall burden of anaemia in the population, thereby driving the demand for EPO drugs.

Restraint:

Potential adverse effects

The erythropoietin drug market faces potential restraints linked to the occurrence of adverse effects associated with the therapeutic use of these drugs. One significant concern is the risk of cardiovascular events, including thrombosis and hypertension, associated with the administration of erythropoietin drugs. Furthermore, another potential adverse effect is the development of pure red cell aplasia (PRCA), a rare but serious condition characterized by a sudden halt in the production of red blood cells.

Opportunity:

Increased healthcare awareness

Increased healthcare awareness serves as a pivotal driver in the erythropoietin drugs market. As awareness about health conditions, including anemia, continues to rise among patients and healthcare professionals, there is a heightened recognition of the significance of erythropoietin drugs in managing anemia-associated complications. Moreover, patients are increasingly seeking timely and effective treatments for conditions like chronic kidney disease and other disorders where erythropoietin drugs play a vital role. These factors drive market demand.

Threat:

Emerging alternatives

As scientific and medical research progresses, new therapeutic options, including non-pharmacological interventions and alternative drug therapies, are gaining attention and posing a challenge to the dominance of erythropoietin drugs. Moreover, the increasing availability and adoption of biosimilars in the market can lead to pricing pressures and market share competition, impacting the revenue of branded erythropoietin drugs.

Covid-19 Impact

The erythropoietin drug market experienced notable impacts from the COVID-19 pandemic. Non-urgent medical procedures and treatments, including those involving erythropoietin drugs for anaemia, were deferred or delayed, affecting the overall market demand. Additionally, disruptions in the pharmaceutical supply chain, restrictions on movement, and workforce shortages posed obstacles to the production and distribution of erythropoietin drugs.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to hold the largest share. Cancer patients frequently experience anaemia due to the effects of the disease itself or as a side effect of chemotherapy. Erythropoietin drugs, such as epoetin-alfa, are employed to address anaemia in cancer patients by stimulating the production of red blood cells. Moreover, erythropoietin therapies improve the patient's well-being, potentially allowing for more effective cancer treatment by maintaining adequate levels of oxygen-carrying red blood cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics are designed to mimic the natural function of erythropoietin in stimulating the production of red blood cells in the bone marrow. Erythropoietin biologics are commonly used to address anaemia associated with chronic kidney disease, cancer chemotherapy, and certain other medical conditions. Additionally, biologics, including erythropoietin-based agents, contribute significantly to patient care by offering targeted and effective treatments for anaemia.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, technological innovation, and a high prevalence of conditions. The prevalence of anaemia, particularly in CKD patients undergoing dialysis and individuals undergoing cancer treatments, has fuelled the demand for erythropoietin drugs in North America. Moreover, the region is also at the forefront of biotechnological and pharmaceutical research, driving continuous innovation in erythropoietin drug development.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to its significant contribution to the global pharmaceutical industry. Countries like China and India have emerged as key players in the production and consumption of erythropoietin drugs. The region's pharmaceutical sector benefits from robust research and development activities, fostering innovation and the introduction of new EPO formulations. Additionally, the Asia-Pacific's evolving healthcare infrastructure and increasing healthcare expenditure contribute to the growth of the erythropoietin drug market.

Key players in the market

Some of the key players in the Erythropoietin Drugs Market include Johnson & Johnson Services, Inc., AstraZeneca, Amgen, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc, LG Chem, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories and Roche Diagnostics.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In September 2023, Sun Pharmaceutical Industries Limited announced that it had entered into a licence agreement with American biopharmaceutical company Pharmazz Inc to commercialise an innovative drug, Tyvalzi (Sovateltide) in India.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In October 2020, Novartis and Molecular Partners AG announced collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.

Types Covered:

Biosimilars
Biologics

Products Covered:

Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Other Products

Distribution Channels Covered:

Online Pharmacy
Hospital Pharmacy
Other Distribution Channels

Applications Covered:

Hematology
Cancer
Neurology
Renal Diseases
Other Applications

End Users Covered:

Speciality Clinics
Hospitals
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Erythropoietin Drugs Market, By Type

5.1 Introduction
5.2 Biosimilars
5.3 Biologics

6 Global Erythropoietin Drugs Market, By Product

6.1 Introduction
6.2 Epoetin-alfa
6.3 Epoetin-beta
6.4 Darbepoetin-alfa
6.5 Other Products

7 Global Erythropoietin Drugs Market, By Distribution Channel

7.1 Introduction
7.2 Online Pharmacy
7.3 Hospital Pharmacy
7.4 Other Distribution Channels

8 Global Erythropoietin Drugs Market, By Application

8.1 Introduction
8.2 Hematology
8.3 Cancer
8.4 Neurology
8.5 Renal Diseases
8.6 Other Applications

9 Global Erythropoietin Drugs Market, By End User

9.1 Introduction
9.2 Speciality Clinics
9.3 Hospitals
9.4 Other End Users

10 Global Erythropoietin Drugs Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Johnson & Johnson Services, Inc.
12.2 AstraZeneca
12.3 Amgen, Inc.
12.4 Novartis AG
12.5 Teva Pharmaceutical Industries Ltd.
12.6 Pfizer Inc
12.7 LG Chem
12.8 F. Hoffmann-La Roche Ltd.
12.9 Sun Pharmaceutical Industries Ltd.
12.10 Intas Pharmaceuticals Ltd.
12.11 Dr. Reddy's Laboratories Ltd
12.12 Ranbaxy Laboratories
12.13 Roche Diagnostics

エリスロポエチン製剤市場の2030年までの予測： タイプ別、製品別、流通チャネル別、用途別、エンドユーザー別、地域別の世界分析

Erythropoietin Drugs Market Forecasts to 2030 - Global Analysis By Type (Biosimilars and Biologics), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Products), Distribution Channel, Application, End User and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のエリスロポエチン製剤市場：タイプ別

第6章 世界のエリスロポエチン製剤市場：製品別

第7章 世界のエリスロポエチン製剤市場：流通チャネル別

第8章 世界のエリスロポエチン製剤市場：用途別

第9章 世界のエリスロポエチン製剤市場：エンドユーザー別

第10章 世界のエリスロポエチン製剤市場：地域別

第11章 主な発展

第12章 企業プロファイル